> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# MHRA launches Women’s Health Programme to close evidence gaps in medicines and medical devices
- URL: https://med-techinsights.com/mhra-launches-womens-health-programme-to-close-evidence-gaps-in-medicines-and-medical-devices/
- Published: 2026-11-20T08:24:49.000Z
- Updated: 2026-11-20T08:24:49.000Z
- Author: Chris Whitehouse
- Tags: Femtech, Medical Device Manufacturing

***Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at*** [***Whitehouse Communications***](http://www.whitehousecomms.com/?ref=med-techinsights.com)***, and a Trustee of the*** [***Bios Centre***](https://bioscentre.org/?ref=med-techinsights.com) ***for bioethics reports on the MedTech regulator’s new Women’s Health Programme.***

---

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched (16th November 2026) a new [five-year Women’s Health Programme](https://www.gov.uk/government/publications/mhra-womens-health-programme-2026-2030?utm%5Fmedium=email&utm%5Fcampaign=govuk-notifications-topic&utm%5Fsource=f4705afe-036d-454d-a5c9-4a81933ab363&utm%5Fcontent=immediately) aimed at addressing longstanding evidence gaps in the development, regulation and monitoring of medicines and medical devices used by women. The initiative will run from 2026 to 2030 and forms part of the regulator’s wider Strategy 2030 commitment to reduce health inequalities through more proactive regulation.

The programme responds to concerns that women remain underrepresented in healthcare research despite accounting for 51% of the UK population. According to the MHRA, evidence underpinning many medicines, medical devices and healthcare technologies does not adequately reflect women’s biological characteristics, life stages or healthcare needs.

In the programme foreword, the agency describes the issue as a "system-level" challenge affecting access to treatment, patient confidence and health outcomes across women’s lives.

Analysis conducted by the MHRA found that among 4,616 UK clinical trial applications submitted between 2019 and 2023, pregnant women were represented in only 1.1% of studies and breastfeeding women in just 0.6%.

**Four strategic priorities**

The Women’s Health Programme is structured around four core themes:

1. Using data to improve health outcomes for women
2. Supporting innovation and improving the quality of healthcare products for women
3. Enabling more informed treatment decisions during pregnancy and breastfeeding
4. Increasing the MHRA’s reach and impact in women’s health

Through these priorities, the regulator intends to strengthen the evidence base used to assess medicines and medical devices, promote sex-specific research where appropriate, and improve the information available to patients, clinicians and developers of healthcare technologies.

**Implications for the medtech sector**

For the medical technology industry, the programme signals a stronger regulatory focus on generating evidence that reflects sex-based differences in safety, effectiveness and user experience. The MHRA said it aims not only to identify differences after products reach the market but to ensure women's health considerations are integrated throughout product development, assessment and post-market surveillance.

The agency also highlights women's health as a significant innovation opportunity. The programme notes that the UK's FemTech sector generates annual turnover of nearly £300 million and has attracted £544 million in investment. The regulator believes that improved evidence generation and clearer regulatory pathways could support further growth while maintaining standards of safety, quality and effectiveness.

**Alignment with wider policy objectives**

The initiative aligns with the MHRA's broader Strategy 2030, which identifies reducing inequalities and addressing evidence gaps as a strategic priority. It also complements the Government's renewed Women's Health Strategy for England and wider efforts to improve outcomes across women's healthcare.

Women's Health Minister Baroness Gillian Merron described the programme as a step towards improving the evidence base for treatments and technologies used by women, while MHRA Chief Executive Lawrence Tallon said better evidence would help researchers, innovators and regulators identify where important differences in risk and benefit exist.

**Looking ahead**

The MHRA intends to work with patients, researchers, healthcare professionals, industry and international partners to deliver the programme's objectives. For manufacturers and developers of medicines and medical technologies, the initiative underscores a growing regulatory expectation that evidence generation and product evaluation better reflect women's health needs across the life course.

As regulators globally place greater emphasis on inclusion, real-world evidence and personalised healthcare, the Women’s Health Programme positions the MHRA to play a more active role in shaping how sex-specific evidence is generated, assessed and translated into safer, more effective healthcare products.

The Programme [can be found here](https://www.gov.uk/government/publications/mhra-womens-health-programme-2026-2030?utm%5Fmedium=email&utm%5Fcampaign=govuk-notifications-topic&utm%5Fsource=f4705afe-036d-454d-a5c9-4a81933ab363&utm%5Fcontent=immediately).

*The Author used AI in preparing this article. Comments upon or questions about this article can be addressed to* [*chris.whitehouse@whitehousecomms.com*](mailto:chris.whitehouse@whitehousecomms.com)*.*